939043-30-8

Usage

Uses

Used in Pharmaceutical Industry:
2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-amine is used as a key intermediate in the synthesis of various pharmaceutical compounds, primarily for the development of CNS drugs. Its unique structure and properties make it a valuable component in the creation of medications targeting neurological and psychiatric conditions.
Used in Research and Development:
2,3,4,5-tetrahydro-1H-benzo[c]azepin-7-amine is utilized as a research tool in the study of neuropharmacology and drug development. Its potential therapeutic effects in the treatment of depression, anxiety, and related psychiatric disorders make it an important subject of investigation for scientists and researchers working in the field of CNS drug discovery and development.

Upstream product

• 66361-68-0 (E)-6-bromo-3,4-dihydronaphthalen-1(2H)-one oxime 
• 66361-67-9 6-bromo-3,4-dihydro-2H-naphthalen-1-one 
• 444588-42-5 7-(2,5-dimethyl-pyrrol-1-yl)-2,3,4,5-tetrahydro-benzo[c]azepin-1-one 
• 1022954-85-3 6-aminotetralin-1-one oxime 
• 22246-68-0 7-amino-2,3,4,5-tetrahydro-1H-benzo[c]azepin-1-one 
• 3470-53-9 6-amino-1-tetralone 
• 648876-22-6 7-(2,5-dimethyl-pyrrol-1-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepine 

Downstream Products

• 939043-33-1 [(3S)-4-[(2-{[(1,1-Dimethylethyl)oxy]carbonyl}-2,3,4,5-tetrahydro-1H-2-benzazepin-7-yl)amino]-4-oxo-3-({[(phenylmethyl)oxy]carbonyl}amino)butyl](dimethyl)sulfonium iodide 
• 939043-34-2 1,1-Dimethylethyl 7-[(3S)-2-oxo-3-({[(phenylmethyl)oxy]carbonyl}amino)-1-pyrrolidinyl]-1,3,4,5-tetrahydro-2H-2-benzazepine-2-carboxylate 
• 939043-32-0 1,1-Dimethylethyl 7-[(N-{[(phenylmethyl)oxy]carbonyl}-L-methionyl)amino]-1,3,4,5-tetrahydro-2H-2-benzazepine-2-carboxylate 
• 939043-31-9 tert-butyl 7-amino-1,3,4,5-tetrahydro-2H-benzo[c]azepine-2-carboxylate 
• 444588-28-7 7-benzyloxycarbonylamino-1,3,4,5-tetrahydro-benzo[c]azepine-2-carboxylic acid benzyl ester 

Relevant academic research and scientific papers

HETEROARYL COMPOUNDS AND USES THEREOF

The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. It has now been found that compounds of this invention, and pharmaceutically acceptable compositions thereof, are effective as inhibitors of one or more protein kinases. Such compounds have general formula I or a pharmaceutically acceptable salt thereof, wherein Ring A, Ring B, W, Ry, R3 and R4 are as defined herein.

The discovery of potent and long-acting oral factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs

The discovery and evaluation of potent and long-acting oral sulfonamidopyrrolidin-2-one factor Xa inhibitors with tetrahydroisoquinoline and benzazepine P4 motifs are described. Unexpected selectivity issues versus tissue plasminogen activator in the form

BICYCLOANILINE DERIVATIVE

The invention relates to a compound of a general formula (I): wherein A1 and A2 each mean a nitrogen atom or an optionally-substituted methine group; Ring B means a 5-membered to 7-membered aliphatic ring, or a spiro or bicyclo ring formed from the aliphatic ring and any other 3-membered to 7-membered aliphatic ring; R1 means a hydrogen atom, or an optionally-substituted C1-C6 alkyl group, or an optionally-substituted aryl, aralkyl or heteroaryl group; R2 means an optionally-substituted aryl, aralkyl or heteroaryl group; and X means a group of =NH or =O, etc. Based on its excellent Wee1 kinase-inhibitory effect, the compound of the invention has cell growth-inhibitory effect and has an additive/synergistic effect with any other anticancer agent, and is therefore useful in the field of medicine.

1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors

The invention relates to chemical entities of formula (I): and/or pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds

Synthesis and biological evaluation of benzazepine oxazolidinone antibacterials

Novel benzazepine oxazolidinone antibacterials were synthesized and evaluated against clinically relevant susceptible and resistant organisms. The effect of ring nitrogen position and N-substitution on antibacterial activity is examined.